Meningococcus (Neisseria meningitidis Infection) Drug Development Pipeline Study, H2 2018
Meningococcus (Neisseria meningitidis Infection) Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Meningococcus (Neisseria meningitidis Infection) pipeline products.
DISEASE OVERVIEW
Meningococcal infection is one of the serious and death causing infections worldwide. In particular, Sub%li%Saharan Africa frequently witnesses meningococcus outbreaks with 1 person per 100 being infected. In rest of the world, the prevalence is at an estimated 0.3 to 3 per 100,000 people.
The infection is caused by the bacteria%li%Neisseria meningitides and affects the human spinal cord, lining of brain. Purulent spinal fluid or detection of the bacteria in the fluid or blood is currently used to determine the meningococcus infected persons.
Meningococcal vaccines vary largely in price from around $2.5 to $117 per dose. Currently available vaccines include%li%bivalent, trivalent and tetravalent. Further, the disease has high fatality rates of around 50% if left untreated.
Accordingly, to increase their share in global meningococcus market, companies are aggressively investing their financial and R&D efforts in meningococcal infection pipeline. 10+ companies are participating in the pipeline development of meningococcus, which include%li%Beijing Minhai Biotechnology Co Ltd, Biological E Ltd, Chongqing Zhifei Biological Products Co Ltd, GlaxoSmithKline Plc, ImmunoBiology Ltd, Neoculi Pty Ltd, Pfizer Inc, Sanofi Pasteur SA, Serum Institute of India Ltd, Tianjin CanSino Biotechnology Inc, Wellstat Vaccines LLC.
REPORT DESCRIPTION
The Meningococcus (Neisseria meningitidis Infection) pipeline guide presents complete overview of drugs currently being developed for Meningococcus (Neisseria meningitidis Infection). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Meningococcus (Neisseria meningitidis Infection) pipeline candidate.
Research and Development progress along with latest news related to each of the Meningococcus (Neisseria meningitidis Infection) pipeline candidates is included.
Major companies participating in therapeutic development of Meningococcus (Neisseria meningitidis Infection) are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Meningococcus (Neisseria meningitidis Infection) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Meningococcus (Neisseria meningitidis Infection) clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Meningococcus (Neisseria meningitidis Infection) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF MENINGOCOCCUS (NEISSERIA MENINGITIDIS INFECTION) PIPELINE REPORT INCLUDES
DISEASE OVERVIEW
Meningococcal infection is one of the serious and death causing infections worldwide. In particular, Sub%li%Saharan Africa frequently witnesses meningococcus outbreaks with 1 person per 100 being infected. In rest of the world, the prevalence is at an estimated 0.3 to 3 per 100,000 people.
The infection is caused by the bacteria%li%Neisseria meningitides and affects the human spinal cord, lining of brain. Purulent spinal fluid or detection of the bacteria in the fluid or blood is currently used to determine the meningococcus infected persons.
Meningococcal vaccines vary largely in price from around $2.5 to $117 per dose. Currently available vaccines include%li%bivalent, trivalent and tetravalent. Further, the disease has high fatality rates of around 50% if left untreated.
Accordingly, to increase their share in global meningococcus market, companies are aggressively investing their financial and R&D efforts in meningococcal infection pipeline. 10+ companies are participating in the pipeline development of meningococcus, which include%li%Beijing Minhai Biotechnology Co Ltd, Biological E Ltd, Chongqing Zhifei Biological Products Co Ltd, GlaxoSmithKline Plc, ImmunoBiology Ltd, Neoculi Pty Ltd, Pfizer Inc, Sanofi Pasteur SA, Serum Institute of India Ltd, Tianjin CanSino Biotechnology Inc, Wellstat Vaccines LLC.
REPORT DESCRIPTION
The Meningococcus (Neisseria meningitidis Infection) pipeline guide presents complete overview of drugs currently being developed for Meningococcus (Neisseria meningitidis Infection). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Meningococcus (Neisseria meningitidis Infection) pipeline candidate.
Research and Development progress along with latest news related to each of the Meningococcus (Neisseria meningitidis Infection) pipeline candidates is included.
Major companies participating in therapeutic development of Meningococcus (Neisseria meningitidis Infection) are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Meningococcus (Neisseria meningitidis Infection) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Meningococcus (Neisseria meningitidis Infection) clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Meningococcus (Neisseria meningitidis Infection) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF MENINGOCOCCUS (NEISSERIA MENINGITIDIS INFECTION) PIPELINE REPORT INCLUDES
- Panorama of Meningococcus (Neisseria meningitidis Infection) pipeline markets including statistics on therapeutic drugs and companies involved
- Meningococcus (Neisseria meningitidis Infection) Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
- Meningococcus (Neisseria meningitidis Infection) pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
- Overview of companies participating in Meningococcus (Neisseria meningitidis Infection) pipeline with short introduction to their businesses and pipeline projects
- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
- Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Meningococcus (Neisseria meningitidis Infection) pipeline therapeutics
- Get clear understanding of the entire Meningococcus (Neisseria meningitidis Infection) pipeline, with details on active projects
- Get in detail information of each product with updated information on each project along with key milestones
- Know the list of companies participating in global Meningococcus (Neisseria meningitidis Infection) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
I. KEY FINDINGS
1. Companies Investing in Meningococcus Pipeline include-
Number of Companies with Meningococcus projects in pre-clinical Development-
Number of Companies with Meningococcus projects in Clinical Development-
Meningococcus Pipeline Companies based in Americas
Meningococcus Pipeline Companies based in Europe
Meningococcus Pipeline Companies based in Asia Pacific
Meningococcus Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Meningococcus Pipeline Agents in pre- clinical/Discovery stage of Development
Meningococcus Pipeline Agents in Clinical Development stage
Meningococcus Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Meningococcus Pipeline agents
II. INSIGHTS INTO MENINGOCOCCUS PIPELINE
1. Disease Overview
Introduction to Meningococcus
Symptoms and Causes of Meningococcus
Treatment or Prevention Options for Meningococcus
Other Details
2. Phase wise Pipeline Compounds
Meningococcus Pipeline- Pre- Clinical/Discovery stage Drugs
Meningococcus Pipeline- Phase 1 stage Drugs
Meningococcus Pipeline- Phase 2 stage Drugs
Meningococcus Pipeline- Phase 3 stage Drugs
Meningococcus Pipeline- Pre-Registration stage Drugs
3. Company wise Meningococcus Pipeline Compounds
4. Meningococcus Pipeline by Mechanism of Action
III. MENINGOCOCCUS PIPELINE COMPOUND DETAILS
Meningococcal (A,C,Y, W135) tetra valent vaccine
meningococcal A, C, W, Y vaccine
A, C, Y, W135 meningococcal polysaccharide conjugate vaccine
ABC Meningococcal Vaccine
Men ABCWY
MenBioVax
NCL195
PF-06886992
Men Quad TT
Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W-135, X)
MCV2
Meningococcus B synthetic oligosaccharide conjugate Vaccine
Meningococcus CY polysaccharide conjugate Vaccine
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. MENINGOCOCCUS PIPELINE COMPANY BRIEFS
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
Chongqing Zhifei Biological Products Co Ltd
GlaxoSmithKline Plc
ImmunoBiology Ltd
Neoculi Pty Ltd
Pfizer Inc
Sanofi Pasteur SA
Serum Institute of India Ltd
Tianjin CanSino Biotechnology Inc
Wellstat Vaccines LLC
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL MENINGOCOCCUS PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
1. Companies Investing in Meningococcus Pipeline include-
Number of Companies with Meningococcus projects in pre-clinical Development-
Number of Companies with Meningococcus projects in Clinical Development-
Meningococcus Pipeline Companies based in Americas
Meningococcus Pipeline Companies based in Europe
Meningococcus Pipeline Companies based in Asia Pacific
Meningococcus Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Meningococcus Pipeline Agents in pre- clinical/Discovery stage of Development
Meningococcus Pipeline Agents in Clinical Development stage
Meningococcus Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Meningococcus Pipeline agents
II. INSIGHTS INTO MENINGOCOCCUS PIPELINE
1. Disease Overview
Introduction to Meningococcus
Symptoms and Causes of Meningococcus
Treatment or Prevention Options for Meningococcus
Other Details
2. Phase wise Pipeline Compounds
Meningococcus Pipeline- Pre- Clinical/Discovery stage Drugs
Meningococcus Pipeline- Phase 1 stage Drugs
Meningococcus Pipeline- Phase 2 stage Drugs
Meningococcus Pipeline- Phase 3 stage Drugs
Meningococcus Pipeline- Pre-Registration stage Drugs
3. Company wise Meningococcus Pipeline Compounds
4. Meningococcus Pipeline by Mechanism of Action
III. MENINGOCOCCUS PIPELINE COMPOUND DETAILS
Meningococcal (A,C,Y, W135) tetra valent vaccine
meningococcal A, C, W, Y vaccine
A, C, Y, W135 meningococcal polysaccharide conjugate vaccine
ABC Meningococcal Vaccine
Men ABCWY
MenBioVax
NCL195
PF-06886992
Men Quad TT
Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W-135, X)
MCV2
Meningococcus B synthetic oligosaccharide conjugate Vaccine
Meningococcus CY polysaccharide conjugate Vaccine
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. MENINGOCOCCUS PIPELINE COMPANY BRIEFS
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
Chongqing Zhifei Biological Products Co Ltd
GlaxoSmithKline Plc
ImmunoBiology Ltd
Neoculi Pty Ltd
Pfizer Inc
Sanofi Pasteur SA
Serum Institute of India Ltd
Tianjin CanSino Biotechnology Inc
Wellstat Vaccines LLC
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL MENINGOCOCCUS PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
